1SXPD Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €25.68 |
| 52 Week High | €39.60 |
| 52 Week Low | €25.68 |
| Beta | 0 |
| 1 Month Change | -13.54% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -32.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1SXPD | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 0.3% |
| 1Y | n/a | -20.1% | 6.6% |
Return vs Industry: Insufficient data to determine how 1SXPD performed against the UK Life Sciences industry.
Return vs Market: Insufficient data to determine how 1SXPD performed against the UK Market.
Price Volatility
| 1SXPD volatility | |
|---|---|
| 1SXPD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 1SXPD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 1SXPD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,604 | Andreas Reisse | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXPD fundamental statistics | |
|---|---|
| Market cap | €3.86b |
| Earnings (TTM) | €149.69m |
| Revenue (TTM) | €957.09m |
25.8x
P/E Ratio4.0x
P/S RatioIs 1SXPD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXPD income statement (TTM) | |
|---|---|
| Revenue | €957.09m |
| Cost of Revenue | €634.48m |
| Gross Profit | €322.61m |
| Other Expenses | €172.93m |
| Earnings | €149.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 33.71% |
| Net Profit Margin | 15.64% |
| Debt/Equity Ratio | 25.3% |
How did 1SXPD perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield16%
Payout RatioDoes 1SXPD pay a reliable dividends?
See 1SXPD dividend history and benchmarks| SCHOTT Pharma KGaA dividend dates | |
|---|---|
| Ex Dividend Date | Feb 05 2025 |
| Dividend Pay Date | Feb 07 2025 |
| Days until Ex dividend | 26 days |
| Days until Dividend pay date | 28 days |
Does 1SXPD pay a reliable dividends?
See 1SXPD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 09:55 |
| End of Day Share Price | 2024/12/12 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SCHOTT Pharma AG & Co. KGaA is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Jain | Barclays |
| Victoria Lambert | Berenberg |
| Hugo Solvet | BNP Paribas Exane |